Ser93
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.1.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser93  -  SET iso2 (human)

Site Information
FVNHPQVsALLGEED   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 19009801

In vivo Characterization
Methods used to characterize site in vivo:
immunoassay ( 1 ) , mass spectrometry (in vitro) ( 2 ) , mutation of modification site ( 1 , 2 ) , western blotting ( 1 )
Disease tissue studied:
lung cancer ( 1 ) , non-small cell lung cancer ( 1 ) , non-small cell lung adenocarcinoma ( 1 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 2 ) , A549 (pulmonary) ( 1 ) , HL-1 (myocyte) ( 2 )

Upstream Regulation
Putative in vivo kinases:
PIK3CG (human) ( 2 )
Kinases, in vitro:
PIK3CG (human) ( 2 )
Treatments:
wortmannin ( 2 )

Downstream Regulation
Effects of modification on SET iso2:
molecular association, regulation ( 2 ) , phosphorylation ( 2 ) , receptor desensitization, induced ( 2 )
Effects of modification on biological processes:
signaling pathway regulation ( 2 )
Induce interaction with:
PPP2CA (human) ( 2 )

References 

1

De Palma RM, et al. (2019) The NMR-based characterization of the FTY720-SET complex reveals an alternative mechanism for the attenuation of the inhibitory SET-PP2A interaction. FASEB J 33, fj201802264R
30917007   Curated Info

2

Vasudevan NT, et al. (2011) Inhibition of Protein Phosphatase 2A Activity by PI3Kγ Regulates β-Adrenergic Receptor Function. Mol Cell 41, 636-48
21419339   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.